Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment

Launched by CHILDREN'S CANCER GROUP, CHINA · Aug 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Brentuximab vedotin (Bv) for children, adolescents, and young adults who have recently been diagnosed with classical Hodgkin lymphoma (cHL). The goal is to see if using Bv can improve early treatment responses and reduce the need for radiation therapy, which can have long-term side effects. By replacing some traditional chemotherapy drugs with Bv, the researchers hope to increase the number of patients who show a complete response to treatment early on. They aim to maintain a high rate of long-term survival while minimizing the use of radiation.

To participate in this trial, individuals must be between 2 and 34 years old and have a confirmed diagnosis of classical Hodgkin lymphoma. They must also have good organ function and be able to provide consent or have a parent or guardian do so. However, those with certain conditions, such as a different type of lymphoma or specific immune system issues, as well as pregnant or breastfeeding individuals, are not eligible. Participants can expect regular check-ups and assessments during the trial to monitor their response to the treatment and overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages \>=2\~\<35 years at the time of enrollment;
• • Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;
• • Adequate organ function;
• • Patients and/or their parents or legal guardians sign a written informed consent;
• Exclusion Criteria:
• • Patients with nodular lymphocyte-predominant HL;
• • Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.
• • Patients who are pregnant; Lactating females who plan to breastfeed.
• • Patients who received systemic corticosteroids within 28 days of enrollment on this protocol